Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS-233 SR for Vasomotor Symptoms in Menopause
NCT00421031Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in vasomotor symptoms (5 arms), sponsored by Pfizer. Primary endpoint: Relief of Vasomotor Symptoms. Started Dec 2003; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00421031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421031.